'The ur­gency is in­creas­ing': Mod­er­na spot­lights vac­cine, or­phan drug pro­grams, as it plots growth be­yond Covid

At its R&D day two years ago, Mod­er­na was still anx­ious­ly await­ing Phase III da­ta on its Covid-19 vac­cine. In a pre­view, CEO Stéphane Ban­cel talked about the next 12 months be­ing “the biggest in­flec­tion point ever” if the shot got launched — as he laid out his new vi­sion for a high-fly­ing biotech vault­ed three to four years ahead by the pan­dem­ic.

“We have 20 drugs in clin­i­cal de­vel­op­ment to­day,” Ban­cel told End­points News at the time. “Could we, in 18 months, 24 months from now have 40? 50? I think it’s pos­si­ble.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER